标准化急性髓系白血病分类系统:国际专家组的观点
世界卫生组织(WHO)与国际共识分类(ICC)于2022年各自提出急性髓系白血病分类系统,二者在基因组定义和原始细胞计数上方向一致,但在诊断标准上存在重大分歧。本文评述两系统的优缺点,指出共存与应用给患者、临床医生、血液病理学家、研究申办方和监管机构带来过度挑战,并提出统一路线图。
要点
- WHO与ICC 2022两套急性髓系白血病分类系统在诊断标准上存在重大分歧。
- 两系统均向基因组疾病定义发展并降低原始细胞计数的重要性。
- 两系统共存影响诊断、患者沟通、管理策略、临床试验入组与药物开发。
核心结论
- 两套急性髓系白血病分类系统在诊断标准上的分歧威胁医疗提供者诊断疾病、与患者及其他医疗提供者沟通、以及为患者提供适当且一致管理策略的能力。
- 临床试验入组资格、标准化疗效评估以及最终的药物开发和监管路径也可能受到两系统差异的负面影响。
- 作者强调统一两套分歧分类系统的紧迫性,并提出实现统一的路线图。
研究设计与样本
- 本文为观点类文章(Viewpoint),由国际专家组撰写,评述WHO与国际共识分类(ICC)两套急性髓系白血病分类系统的优缺点。
主要发现
- 两系统均适当转向基因组疾病定义并降低原始细胞计数的重要性,但在何为急性髓系白血病诊断上存在重大分歧。
- 两系统共存与应用对患者、临床医生、血液病理学家、研究申办方和监管机构构成过度挑战。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The existence of two acute myeloid leukaemia classification systems-one put forth by WHO and one by the International Consensus Classification in 2022-is concerning. Although both systems appropriately move towards genomic disease definitions and reduced emphasis on blast enumeration, there are consequential disagreements between the two systems on what constitutes a diagnosis of acute myeloid leukaemia. This fundamental problem threatens the ability of heath-care providers to diagnose acute myeloid leukaemia, communicate with patients and other health-care providers, and deliver appropriate and consistent management strategies for patients with the condition. Clinical trial eligibility, standardised response assessments, and eventual drug development and regulatory pathways might also be negatively affected by the discrepancies. In this Viewpoint, we review the merits and limitations of both classification systems and illustrate how the coexistence, as well as application of both systems is an undue challenge to patients, clinicians, hematopathologists, sponsors of research, and regulators. Lastly, we emphasise the urgency and propose a roadmap, by which the two divergent classification systems can be harmonised.
引用
- Shallis RM, Daver N, Altman JK, et al. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. Lancet Haematol. 2023. PMID: 37572683. doi:10.1016/S2352-3026(23)00159-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。